换一批Nonclinical safety, tolerance and pharmacodynamics evaluation for meplazumab treating chloroquine-resistant <i>Plasmodium falciparum</i>.
第一作者：
Kun,Zhang
第一单位：
College of Life Science and Bioengineering, School of Science, Beijing Jiaotong University, Beijing 100044, China.;National Translational Science Center for Molecular Medicine & Department of Cell Biology, the Fourth Military Medical University, Xi'an 710032, China.
作者：
关键词
ADA, anti-drug antibodyADCC, antibody-dependent cell-mediated cytotoxicityAntimalarial therapyCD147EfficacyFFPE, formalin-fixed paraffin-embeddedFab, variable region of monoclonal antibodyFc, crystalline region of monoclonal antibodyHPLC, high-performance liquid chromatographyHRP, horseradish peroxidaseIR, inhibition rateMeplazumabNOG mice, NOD/Shi-scid/IL-2Rγ null miceNonclinicalPBS, phosphate buffered salinePC50, median parasite clearance timePlasmodium falciparumPr, parasitemiaRAP2, rhoptry-associated protein 2RBCs, red blood cellsRH5, reticulocyte-binding protein homolog 5RO, receptor occupancySD rats, Sprague–Dawley ratsSafetyTCA, trichloroacetic acidToleranceWHO, World Health OrganizationhuRBCs, human red blood cellsmAbs, monoclonal antibodies
DOI
10.1016/j.apsb.2020.06.011
PMID
33088688
发布时间
2020-10-23
- 浏览2
Acta pharmaceutica Sinica. B
2020年10卷9期
1680-1693页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
